DHRS2 and otitis media: We compared otitis media outcomes in infants randomised to either a combination of SynflorixTM (PHiD-CV10, with protein D of NTHi) and Prevenar13TM (PCV13, with 3, 6A, and 19A), with recommended schedules for each vaccine alone.